Figure 3
From: Analysis of Potential Biomarkers and Modifier Genes Affecting the Clinical Course of CLN3 Disease
Relative mRNA expression of DUSP2. (A) The relative mRNA expression of DUSP2 in lymphocytes derived from CLN3 patients receiving anticonvulsive medication compared with age- and gender-matched controls was measured by RT-PCR and normalized to RPS18 expression. The patients were 14, 13 and 14 years old (P14M, male; P13F, female; P14F, female) and were all homozygous for the 1-kb deletion in the CLN3 gene. They were classified as having average (P14M), slow (P13F) and rapid disease progression (P14F). (B) The relative mRNA expression of Dusp2 in CbCln3Δex7/8 cerebellar precursor cells compared with wild-type cells was measured by RT-PCR and normalized to Actb expression. Data are means ± SD of three independent RT-PCR experiments. *P < 0.05 compared with controls; **P < 0.01 compared with controls; ***P < 0.001 compared with controls.